

# PRESS RELEASE



September 28, 2018, Lund, Sweden

## **Invitation to conference call regarding Immunovia's autoimmune diseases strategy on October 8, 2018**

**Immunovia invites to a teleconference (in English) for investors, analysts and media on October 8, 2018 at 3:00 – 4:00 p.m CET.**

LUND, Sweden — Immunovia announced recently that a new study confirms that IMMray™ blood test successfully addresses one of the major challenges in autoimmune testing.

The capability of IMMray™ biomarker signatures to diagnose CCP negative rheumatoid arthritis patients with an accuracy over 90% is a remarkable breakthrough. These exceptionally good results together with the two earlier reported studies showing very high accuracies for the differential diagnosis of the four main autoimmune diseases - rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome and systemic vasculitis (press release March 7, 2017 and press release January 12, 2017), resulted in a strategic focus on rheumatoid arthritis.

Immunovia has since the announcement of these results worked diligently to design studies in collaboration with the company's Key Opinion Leader network to further verify and validate these results and commence development of a commercial assay for this important diagnostic unmet need.

The telephone conference will cover Immunovia's autoimmune diseases strategy presented by Mats Grahn, CEO, Immunovia and Laura Chirica, CCO, Immunovia. The Q&A session will end the call.

To attend, please dial-in at one of the numbers below from:

### **Participant dial in number**

SE: +46856642662  
BE: +3224040635  
CH: +41225675548  
DE: +496922229046  
DK: +4535445579  
FR: +33170750712  
UK: +442030089801  
NL: +207168416  
NO: +4723500254  
US: +18557532235

### **For questions as well as for timing of interviews:**

[ir@immunovia.com](mailto:ir@immunovia.com)

On the Immunovia website under Investors/Audio Gallery (<https://immunovia.com/investors/audio-gallery/>) there will be an MP3 file for those who want to listen to the conference call later, the file is available within two hours of the end of the conference call.

**For further information, please contact:**

**Mats Grahn**

Chief Executive Officer, CEO, Immunovia

Tel.: +46-70-5320230

Email: mats.grahn@immunovia.com

**About Immunovia**

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring.

(Source: [www.immunovia.com](http://www.immunovia.com))

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit [www.immunovia.com](http://www.immunovia.com).

**About Rheumatoid Arthritis (RA)**

Rheumatoid arthritis is a long-term condition that causes pain, swelling and stiffness in the joints. The symptoms usually affect the hands, feet and wrists. There may be periods where symptoms become worse, known as flare-ups or flares. A flare can be difficult to predict, but with treatment it's possible to decrease the number of flares and minimise or prevent long-term damage to the joints. Some people with rheumatoid arthritis also experience problems in other parts of the body, or more general symptoms such as tiredness and weight loss.

In US and Europe, 5-7 Million is the estimated number of patients living with RA and more than 250.000 new cases are diagnosed every year. Many more than these who actually have RA need to be tested since overlapping symptoms to early stage RA due to other causes are common. Due to its large patient population, RA leads to substantial costs for individual patients and healthcare systems as a result of symptoms, loss of productivity, long-term co-morbidities, and hospitalisation. The annual economic burden of RA in the US exceeds \$19 billion, based on direct costs such as hospitalisation, treatment, and loss of productivity.

Recent studies showed that as many as 51% of patients with suspected autoimmune or immune disorders are initially misdiagnosed, in part because of ambiguous laboratory test results. Clinicians warn that misdiagnosis of systemic autoimmune diseases can have serious consequences. Currently the gold standard is to test for anti-cyclic citrullinated peptide (anti-CCP), an auto-antibody present in an estimated 70-75% of rheumatoid arthritis patients.

The global market for RA testing is growing strongly and estimated to reach Euros 2.5 billion by 2024.

###